Rheumatoid arthritis

Caring for older Americans’ teeth and gums is essential, but Medicare generally doesn’t cover that cost

Retrieved on: 
Friday, April 19, 2024

As dentistry scholars, we believe Koop also deserves credit for something else.

Key Points: 
  • As dentistry scholars, we believe Koop also deserves credit for something else.
  • Americans who rely on the traditional Medicare program for their health insurance get no help from that program with paying their dental bills aside from some narrow exceptions.
  • This group includes some 24 million people over 65 – about half of all the people who rely on Medicare for their health insurance.

‘Medically necessary’ exceptions

  • The list of circumstances that would lead patients to be eligible is short.
  • Some examples include patients scheduled for organ transplants or who have cancer treatment requiring radiation of their jaws.
  • But we believe that dental care is necessary for everyone, especially for older people.

Chew, speak, breathe

  • While many working Americans get limited dental coverage through their employers, those benefits are usually limited to as little as $1,000 per year.
  • And once they retire, Americans almost always lose even that basic coverage.
  • Rich Americans with Medicare coverage are almost three times more likely to receive dental care compared to those with low incomes.

Connected to many serious conditions

  • Having diabetes makes you three times as likely to develop gum disease because diabetes compromises the body’s response to inflammation and infection.
  • At the same time, treating diabetes patients for gum disease can help control their blood sugar levels.

Chemo can damage your teeth


Many cancer treatments can damage teeth, especially for older adults. As a result, Medicare has started to reimburse for dental bills tied to tooth decay or other oral conditions after they get chemotherapy or radiation treatment.

More than nice to have

  • Doctors and dentists are educated separately, and doctors learn very little about dental conditions and treatments when they’re in medical school.
  • Most dental electronic health records aren’t linked to medical systems, hindering comprehensive care and delivery of dental care to those in need.
  • Medical insurance was designed specifically to cover large, unpredictable expenses, while dental insurance was intended to mainly fund predictable and lower-cost preventive care.

Medicare Advantage plans

  • Until Medicare expands coverage to include preventive dental services for everyone, alternative plans such as Medicare Advantage, through which the federal government contracts with private insurers to provide Medicare benefits, serve as a stopgap.
  • In 2016, only 21% of beneficiaries in traditional Medicare had purchased a stand-alone dental plan, whereas roughly two-thirds of Medicare Advantage enrollees had at least some dental benefits through their coverage.


Frank Scannapieco is affiliated with The Task Force on Design and Analysis in Oral Health Research, and consults for the Colgate-Palmolive Company. Ira Lamster is a member of the Santa Fe Group. He currently receives consulting fees from Colgate, and research support from the CareQuest Institute.

EQS-News: Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions

Retrieved on: 
Wednesday, April 10, 2024

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.

Key Points: 
  • In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.
  • Grünenthal owns 51 percent of the new enterprise Grünenthal Meds and intends to acquire the remaining share in 2026.
  • Aachen, Germany, 25 March 2024 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.
  • The 2023 results were driven by strong business performance in the United States, Latin America and Europe.

Breakthroughs in Kexing Biopharm's Overseas Efforts: Qualification of Two Licensed Products for GMP Audits in Egypt

Retrieved on: 
Tuesday, April 2, 2024

In 2022, Kexing Biopharm secured agreements with 24 overseas market customers and commenced the submission of local drug access registration documents.

Key Points: 
  • In 2022, Kexing Biopharm secured agreements with 24 overseas market customers and commenced the submission of local drug access registration documents.
  • The product underwent GMP audits in Egypt, Brazil, and Indonesia respectively in September 2023, February 2024, and March 2024.
  • In 2022, Kexing Biopharm swiftly reached agreements with 23 overseas market customers, initiating the submission of drug access registration documents.
  • By establishing local subsidiaries, Kexing Biopharm strives to accelerate product registration processes and enhance competitiveness in overseas markets.

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

Retrieved on: 
Tuesday, April 2, 2024

SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gilead Sciences has elected to extend the research term of the companies’ ongoing collaboration, originally established in 2019, by an additional two years.

Key Points: 
  • “Gilead’s extension of the research period of this agreement is a testament to the productivity of our collaboration to date.
  • Most importantly, it increases the opportunity for additional clinical candidates and associated milestones to emerge from our work together with the Gilead team,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix.
  • Gilead has an option to license drug candidates resulting from the work, and Nurix retains co-development and co-detail options on up to two programs in the United States, subject to certain restrictions.
  • Upon signing the agreement in 2019, Gilead made an upfront payment of $45.0 million.

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

Retrieved on: 
Tuesday, April 2, 2024

HAMILTON, Bermuda, April 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced plans to initiate a Phase 2b trial with abiprubart in Sjogren’s Disease. Additionally, the company announced data from Cohort 4 of the Phase 2 clinical trial of abiprubart in rheumatoid arthritis. Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 (CD40 ligand) interaction.

Key Points: 
  • HAMILTON, Bermuda, April 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced plans to initiate a Phase 2b trial with abiprubart in Sjogren’s Disease.
  • Additionally, the company announced data from Cohort 4 of the Phase 2 clinical trial of abiprubart in rheumatoid arthritis.
  • Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 (CD40 ligand) interaction.
  • “We believe abiprubart has the potential to provide meaningful benefit to patients suffering from Sjogren’s Disease, a debilitating disorder with no current FDA-approved therapies.

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Retrieved on: 
Thursday, March 28, 2024

WORCESTER, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced its expansion into autoimmune diseases with MB-106, a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”). Mustang and Fred Hutch are in preliminary discussions to explore a potential Phase 1 investigator-sponsored clinical trial to evaluate MB-106 for the treatment of autoimmune diseases.

Key Points: 
  • MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”).
  • Mustang and Fred Hutch are in preliminary discussions to explore a potential Phase 1 investigator-sponsored clinical trial to evaluate MB-106 for the treatment of autoimmune diseases.
  • “MB-106’s observed safety profile, encouraging efficacy data, and our robust manufacturing capabilities have the potential to translate to improved outcomes for patients with autoimmune diseases.
  • Several antibody therapies targeting CD20 on B-cells have successfully transitioned from cancer to autoimmune diseases, such as rituximab for both lymphoma and rheumatoid arthritis.

China Medical System (867.HK)2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs

Retrieved on: 
Thursday, March 28, 2024

SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results.

Key Points: 
  • SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results.
  • Based on above, CMS has successfully entered into its “New Period” of innovation and internationalization development.
  • 4 innovative drugs have started large-scale clinical application, unveiling CMS’s first year of commercialization era of innovative drugs.
  • Under its compliant and efficient commercialization system, the Company's innovative products and exclusive drugs will grow steadily.

ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, March 28, 2024

Our investigation concerns whether the board of directors of Assertio have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Assertio have breached their fiduciary duties to the company.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • Then, on November 8, 2023, Assertio issued a press release announcing its financial results for its third quarter ("Q3") of 2023.

Pair of Digital Health Research Papers Coauthored by Analysis Group Demonstrate Promises of Wearables to Generate Reliable Site-Less Patient-Reported Outcomes in Rheumatoid Arthritis

Retrieved on: 
Tuesday, April 9, 2024

This technology enables clinicians to develop more sensitive and patient-centric endpoints in RA clinical trials and real-world studies.

Key Points: 
  • This technology enables clinicians to develop more sensitive and patient-centric endpoints in RA clinical trials and real-world studies.
  • "Digital health technologies and machine learning augment patient reported outcomes to remotely characterise rheumatoid arthritis," published in February by Nature's npj Digital Medicine (Creagh, A.P., et al.
  • "Digital health technologies and machine learning augment patient reported outcomes to remotely characterise rheumatoid arthritis."
  • "Patient-centric assessment of rheumatoid arthritis using a smartwatch and bespoke mobile app in a clinical setting."

Global Elbow Replacement Market to surpass $200.4 million by 2031, at a CAGR of 4.2%, says Coherent Market Insights

Retrieved on: 
Monday, April 8, 2024

Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.

Key Points: 
  • Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.
  • As per the market research report, the elbow replacement market was valued at USD 144.2 million in 2023, with a projected CAGR of 4.2% during the forecast period 2024-2031.
  • Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/6663
    In terms of type, the elbow replacement market is segmented into partial elbow replacement and total elbow replacement.
  • Partial elbow replacement is expected to dominate the market, owing to its less invasive nature and shorter recovery time compared to total elbow replacement.